藥物基因學：個別治療的新技術研發

Pharmacogenomics and pharmacogenetics will have a major impact on the future of health care. Pharmacogenetics is the study of the genetic basis for individuals・variable drug responses, and is being applied with increasing frequency at the clinical level. These efforts rely on pharmacogenomics, the genome-wide analysis of the genetic determinants of drug efficacy and toxicity. The cornerstone is the ability to identify genetic variations (polymorphisms) that alter an individuals response to a drug.

This BCC report presents a comprehensive analysis of the current market for pharmacogenomics and its future direction. Currently, the field remains immature. This leaves enormous room for growth. This growth potential over a five-year period to 2009 is assessed. Of particular interest are the markets for SNP identification, genotyping and diagnostics.

Also of interest is the market for specific drugs developed through the use of pharmacogenomics. Only a handful of such therapeutics have entered clinical use as of 2005. In each case, there is an examination of the drug development process, major challenges and achievements and where applicable, the projected market for each of these drugs through 2009.

Table of Contents

• INTRODUCTION
  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • CONTRIBUTIONS TO THE STUDY AND FOR WHOM
  • SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • AUTHORS CREDENTIALS
  • RELATED BCC REPORTS
  • BCC ONLINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: WORLDWIDE PHARMACOGENOMICS MARKET BY TECHNOLOGY SEGMENTS, THROUGH 2009 ($ MILLIONS)
  • Summary Figure: WORLDWIDE PHARMACOGENOMICS MARKET BY TECHNOLOGY SEGMENTS, 2001-2009 ($ MILLIONS)
• OVERVIEW
  • OVERVIEW
  • STREAMLINING CLINICAL TRIALS
    • TIME FRAME FOR DRUG APPROVAL
  • Table 1 DRUG DEVELOPMENT AND FDA APPROVAL PROCESS
    • HIGH COSTS STIFFLE INNOVATION
  • Table 2 NME APPROVALS GRANTED BY FDA (UNITED STATES), 1995-2004
  • Table 3 TOTAL SPENDING ON R&D BY PHRMA COMPANIES, 1999-2003 ($ BILLIONS)
  • Table 4 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
  • Figure 1 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
    • ATTRACTING TRIAL PARTICIPANTS
    • PHARMACOGENOMICS AS A SOLUTION
    • CAVEATS
    • IMPROVING DRUG EFFICACY
  • Table 5 DRUG INEFFICACY, BY THERAPY TYPE (PERCENTAGE OF PATIENTS FAILING TO RESPOND TO THERAPY)
    • REDUCING ADVERSE DRUG REACTIONS
      • FACTORS CONTRIBUTING TO ADVERSE DRUG REACTIONS
      • COSTS OFADVERSE DRUG REACTIONS
  • Table 6 ADVERSE DRUG REACTIONS IN THE UNITED STATES
    • MARKET DRIVERS
    • ROLE OF PHARMACOGENOMICS IN ADR PREVENTION
    • POST-MARKET DRUG FAILURE
      • PROMINENT DRUG WITHDRAWALS
  • Table 7 PROMINENT DRUGS WITHDRAWALS
    • Vioxx
    • Rezulin
    • Pondimin and Redux
    • Seldane
    • Posicor
    • Baycol (Cerivastatin)
    • ROLE OF PHARMACOGENOMICS IN REDUCING DRUG WITHDRAWALS
    • THE SNP CONSORTIUM
  • Table 8 SNP CONSORTIUM MEMBERS
    • THE INTERNATIONAL HAPMAP PROJECT
      • PARTICIPANTS IN THE HAPMAP PROJECT
  • Table 9 HAPMAP PARTICIPANTS AND FUNDING SOURCES
  • Table 10 STRUCTURE OF THE INTERNATIONAL HAPMAP PROJECT
  • Table 10 (CONTINUED)
    • HAPMAP POPULATIONS AND ETHICIAL CONCERNS
    • DATA ACCESSIBILITY AND PATENTABILITY
    • FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES
      • FOOD AND DRUG ADMINISTRATION: NEW GUIDELINES (CONTINUED)
• SNP IDENTIFICATION MARKET
  • SNP IDENTIFICATION MARKET
  • Table 11 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, THROUGH 2009 ($ MILLIONS)
  • Figure 2 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, 2001-2009 ($ MILLIONS)
    • OVERVIEW OF SNP IDENTIFICATION
    • STRATEGIES FOR SNP IDENTIFICATION
      • CANDIDATE GENE SELECTION
      • WHOLE GENOME LINKAGE DISEQUILIBRIUM MAPPING
  • Table 12 EMERGING TECHNOLOGIES IN WHOLE GENOME MAPPING
    • COMBINATION STRATEGIES
    • SNP DATABASES
  • Table 13 MAJOR PRIVATE SNP DATABASES
    • COMPUTATIONAL TOOLS FOR SNP IDENTIFICATION
      • SNPBROWSER, APPLIED BIOSYSTEMS
      • CHROMOSOMEBROWSER?, ORCHID BIOSCIENCES
      • REALSNP, SEQUENOM
      • SNP KNOWLEDGE RESOURCE, ILLUMINA
      • CELERA DISCOVERY SYSTEM?, CELERA
• GENOTYPING MARKET
  • OVERALL MARKET FOR GENOTYPING TECHNOLOGIES
  • Table 14 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, THROUGH 2009 ($ MILLIONS)
  • Figure 3 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, 2001-2009 ($ MILLIONS)
    • GENOTYPING TECHNOLOGY OVERVIEW
    • ALLELIC DISCRIMINATION BY DNA POLYMERASES
  • Table 15 COMPARATIVE ADVANATAGES OF ALLELIC DISCRIMINATION METHODS
    • SINGLE-BASE EXTENSION
    • ALLELE-SPECIFIC EXTENSION
    • PYROSEQUENCING
    • STRUCTURE-SPECIFIC CLEAVAGE
    • TAQMAN ASSAY
  • Table 16 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 4 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
    • ALLELIC DISCRIMINATION BY HYBRIDIZATION
      • MICROARRAYS FOR GENOTYPING
  • Table 17 TOTAL GLOBAL MICROARRAY MARKET AND THAT FOR GENOTYPING APPLICATIONS, THROUGH 2009 ($ MILLIONS)
    • EMERGING TECHNOLOGY FOR ALLELIC DISCRIMINATION BY DNA LIGASES
    • DETECTION OF ALLELE-SPECIFIC PRODUCTS
  • Table 18 COMPARATIVE ADVANATAGES OF DETECTION METHODS
    • MASS SPECTROMETRY
  • Table 19 STRENGTHS AND WEAKENESSES OF MASS SPECTROMETRY FOR GENOTYPING
    • New Developments in Mass Spectrometry for DNA Analysis
  • Table 20 EMERGING TECHNOLOGIES IN DNA MASS SPECTROMETRY
    • FLUORESCENCE RESONANCE ENERGY TRANSFER
    • FLUORESCENCE POLARIZATION
    • LENGTH-BASED DETECTION SYSTEMS
  • Table 21 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 5 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
    • Length-based Detection Systems (continued)
    • COMPARISON OF COST AND THROUGHPUT
  • Table 22 COMPARISON OF GENOTYPING PLATFORMS COST AND THROUGHPUT
• PHARMACOGENOMICS DIAGNOSTICS MARKET
  • OVERALL MARKET FOR PHARAMCOGENOMICS DIAGNOSTICS
  • Table 23 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 6 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, 2001-2009 ($ MILLIONS)
    • MICROARRAYS
      • TECHNOLOGY OVERVIEW
      • PLANAR DNA MICROARRAYS
  • Table 24 MAJOR SUPPLIERS OF PLANAR DNA MICROARRAYS
  • Table 24 (CONTINUED)
    • ELECTRONIC MICROARRAYS
      • Nanochip (Nanogen, San Diego)
    • BEAD MICROARRAYS
    • EMERGING TECHNOLOGY: NANOPARTICLE ARRAYS
      • Verigene (Nanosphere, Chicago, IL)
      • Nanoplex Technologies (Mountain View, CA)
  • Table 25 MAJOR SUPPLIERS OF BEAD MICROARRAYS
    • MARKET FOR MICROARRAYS IN PHARMACOGENOMICS
    • MARKET FOR MICROARRAYS IN PHARMACOGENOMICS
  • Table 26 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, THROUGH 2009 (MILLIONS $)
  • Figure 7 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, 2001-2009 (MILLIONS $)
    • PCR-BASED ASSAYS
  • Table 27 MAJOR SUPPLIERS OF PCR-BASED ASSAYS
    • PCR-BASED TECHNOLOGIES
      • LightCycler (Roche Molecular Systems, Pleasanton, CA)
      • TaqMan DNA probes (Applied Biosystems, Foster City, CA)
      • Invader (Third Wave Technologies, Madison, WI)
      • Tag-It Mutation Assay (Tm Bioscience)
  • Table 28 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, THROUGH 2009 ($ MILLIONS)
  • Figure 8 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, 2001-2009 ($ MILLIONS)
    • IN SITU ANALYSIS
      • TECHNOLOGY
      • HER2 FISH TESTING
      • COMPARISON WITH IHC
  • Table 29 COMPARISON OF FISH AND IHC TESTING FOR HER2
  • Table 30 GLOBAL MARKET FOR IN SITU ASSAYS IN PHARMACOGENOMICS OF BREAST CANCER, THROUGH 2009 ($ MILLIONS)
• PHARMACOGENOMIC THERAPEUTICS BY DISEASE
  • CARDIOVASCULAR DISEASE
    • HEART FAILURE
      • Angiotensin I-Converting Enzyme (ACE)
      • BiDil
      • Projected Market for BiDil
  • Table 31 PROJECTED BIDILR MARKET, THROUGH 2009 ($ MILLIONS)
    • HYPERCHOLESTROLEMIA
  • Table 32 MAJOR PRODUCERS OF STATINS
    • Mechanism of Statins
    • Individual Variation Affects Statin Efficacy
    • STRENGTH Clinical Study of Statins
    • BREAST CANCER
      • BREAST CANCER AND HER2
        • Regulatory Guidelines
        • Emerging Herceptin Combination Market
  • Table 33 GLOBAL MARKET FOR HERCEPTIN, BY REGION, THROUGH 2009 ($ MILLIONS)
    • LEUKEMIA
      • CHRONIC MYELOID LEUKEMIA (CML)
        • Genetic Marker of CML
        • Gleevec
  • Table 34 GLOBAL MARKET FOR GLEEVEC/GLIVEC, BY REGION, THROUGH 2009 ($ MILLIONS)
    • ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    • ACUTE MYELOID LEUKEMIA (AML)
    • LUNG CANCER
      • NON-SMALL CELL LUNG CANCER
        • Clinical Studies on Iressa
        • Fast Track Approval in the US
        • Fast Track Approval in Japan
        • Post-Market Studies of Iressa
  • Table 35 GLOBAL SALES OF IRESSA PRIOR TO FDA ANNOUNCEMENT, 2002-2004 ($ MILLIONS)
    • ASTHMA
      • GENETIC VARIANTS AFFECTING ASTHMA THERAPY
  • Table 36 GENES OF INTEREST IN THE PHARMACOGENOMICS OF ASTHMA
    • MAJOR PLAYERS AND DEVELOPMENTS
  • Table 37 MAJOR PLAYERS IN PHARMACOGENOMICS OF ASTHMA TREATMENT
  • Table 38 GLOBAL MARKET FOR ASTHMA THERAPIES, BY TYPE, THROUGH 2009 ($ MILLIONS)
    • PHARMACOGENOMICS OF HIV/AIDS
      • VIRAL RESISTANCE
      • GENETIC RESISTANCE TESTING
  • Table 39 MAJOR SUPPLIERS OF HIV GENOTYPIC RESISTANCE TESTS
  • Table 40 GLOBAL MARKET FOR HIV RESISTANCE TESTING BY REGION, THROUGH 2009 ($ MILLIONS)
    • Education Gap
    • ABACAVIR, A PHARMACOGENOMICS SUCCESS STORY
  • Table 41 GLOBAL MARKET FOR ABACAVIR, BY REGION, THROUGH 2009 ($ MILLIONS)
  • Figure 9 GLOBAL MARKET FOR ABACAVIR, BY REGION, 2000-2009 ($ MILLIONS)
    • Abacavir, a Pharmacogenomics Success Story (continued)
• PHARMACOGENOMICS OF DRUG METABOLISM
  • DRUG METABOLISM BY CYTOCHROMES
    • P450 ISOZYMES AND PHARMACEUTICALS
  • Table 42 MAJOR CYTOCHROME P450 ISOZYMES
    • P450 Isozyme CYP3A
    • P450 Isozyme CYP2D6
    • P450 Isozyme CYP2C9
    • P450 Isozyme 2C19
    • P450 Isozyme 1A2
    • P450 DIAGNOSTIC TESTING
  • Table 43 GLOBAL MARKET FOR AMPLICHIP ARRAYS IN DIAGNOSTIC USE BY REGION, THROUGH 2009 ($ MILLIONS)
    • P450 TESTING FOR RESEARCH PURPOSES
  • Table 44 MAJOR SUPPLIERS OF CYTOCHROME P450 TESTING FOR RESEARCH PURPOSES
    • COMPETITION WITH PHENOTYPIC ASSAYS
• TECHNOLOGY
  • PATENTS AND COMMERCIALIZATION ISSUES
  • PATENT ANALYSIS
  • PATENT SHARE BY APPLICATION TYPE
  • Table 45 PHARAMCOGENOMICS PATENTS BY TECHNOLOGY, 2004
  • Table 46 PHARAMCOGENOMICS PATENTS BY DISEASE TARGET, 2004
    • PATENT SHARE BY REGION
  • Table 47 PHARMACOGENOMICS PATENTS BY REGION, 2004
  • Table 48 PHARMACOGENOMICS PATENTS BY ASSIGNEE, JANUARY 2004- JANUARY 2005
• INDUSTRY STRUCTURE
  • DRUG MARKET SEGMENTATION
  • MAJOR PHARMACOGENOMICS COMPANIES
  • Table 49 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 ($ MILLIONS)
  • Table 49 (CONTINUED)
  • Figure 10 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 (%)
    • COLLABORATIONS
  • Table 50 KEY COLLABORATIONS IN THE PHARMACOGENOMICS INDUSTRY
    • MYRIAD/ABBOTT
    • CURAGEN/PFIZER
    • DECODE/MERCK
    • DECODE/ROCHE
    • MILLENIUM/BAYER
    • ORCHID BIOSCIENCES/U.K. GOVERNMENT
    • LYNX/INSTITUTE FOR SYSTEMS BIOLOGY
    • NOVARTIS/CELERA
    • THIRD WAVE/RIKEN
    • IMPACT OF RELATED INDUSTRIES
      • NANOTECHNOLOGY
      • BIOINFORMATICS
    • ANALYSIS OF SUCCESSFUL COMPANIES
      • NOVARTIS - GLEEVEC/GLIVEC
        • Disease Target
        • Rapid Movement Through Trials
        • Orphan Drug Approval
        • Strong Brand Recognition
        • Continued Studies Identify New Target Populations
      • AFFYMETRIX, SANTA CLARA, CA
        • Marketing
        • Technical Support
        • Strategic Positioning
        • First Mover Status Maintained
        • Intellectual Property
• INTERNATIONAL ASPECTS
  • UNITED STATES
    • CENTRALIZED PHARMGKB DATABASE
    • FUNDING INITIATIVES
  • EUROPEAN UNION
    • NEW DRUG APPROVALS AND INNOVATION
    • R&D SPENDING IN THE EUROPEAN UNION
    • SOCIAL FACTORS
    • REGULATORY ENVIRONMENT
    • CHEAPER CLINICAL TRIALS
    • MIGRATION TO THE U.S.
  • JAPAN
    • NEW DRUG APPROVALS AND INNOVATION
    • REGULATORY ENVIRONMENT
    • LIMITED ACADEMIC-INDUSTRY COLLABORATION
    • VENTURE CAPITAL
  • OTHER GEOGRAPHIC AREAS
    • INTELLECTUAL PROPERTY
      • Intellectual Property (continued)
• ETHICAL CONSIDERATIONS
  • GENETIC EXCEPTIONALISM
  • PRIVACY
  • DEVELOPING NATIONS
  • DISCRIMINATION
  • GENES AND ENVIRONMENT
• IMPLICATIONS FOR THE FUTURE OF HEALTH CARE
  • EDUCATED DECISION-MAKING
  • RESPONSIBILITY FOR FAILURES
  • OVER-THE-COUNTER TESTS
  • DEFINITION OF ORPHAN DRUGS
    • DEFINITION OF ORPHAN DRUGS (CONTINUED)
• COMPANY PROFILES
  • ABBOTT LABORATORIES, ABBOTT PARK, IL
  • AMERSHAM (NOW GE HEALTHCARE), BUCKINGHAMSHIRE, UK
  • APPLERA CORPORATION, NORWALK, CT
  • ASTRAZENECA, ALDERLEY PARK, UK
  • CURAGEN CORPORATION, NEW HAVEN, CT
  • DAKOCYTOMATION, COPENHAGEN, DENMARK
  • DECODE GENETICS, REYKJAVIK, ICELAND
  • DXS, MANCHESTER, UK
  • ERAGEN, MASDISON, WI
  • FIVEPRIME THERAPEUTICS, SAN FRANCISCO, CA
  • GENAISSANCE PHARMACEUTICALS, NEW HAVEN, CT
  • GENENTECH, SOUTH SAN FRANCISCO, CA
  • GENTRIS, MORRISVILLE, NC
  • GLAXOSMITHKLINE, BRENTFORD, UK
  • HUMAN GENOME SCIENCES, ROCKVILLE, MD
  • ILLUMINA, SAN DIEGO, CA
  • INCYTE, PALO ALTO, CA
  • INTERLEUKIN GENETICS, WALTHAM, MA
  • LUMINEX CORP., AUSTIN, TX
  • MERCK, WHITEHOUSE STATION, NJ
  • MILLENIUM PHARMACEUTICALS, CAMBRIDGE, MA
  • MYRIAD GENETICS, INC., SALT LAKE CITY, UT
  • NANOGEN, SAN DIEGO, CA
  • NANOSPHERE, NORTHBROOK, IL
  • NITROMED, LEXINGTON, MA
  • ORCHID BIOSCIENCES, PRINCETON, NJ
  • PHARMASEQ, MONMOUTH JUNCTION, NJ
  • ROCHE (F. HOFFMANN-LA ROCHE LTD), BASEL, SWITZERLAND
  • SEQUENOM, SAN DIEGO, CA
  • THIRD WAVE, MADISON, WI
  • TM BIOSCIENCE CORP., TORONTO, ON, CANADA
  • WYETH, MADISON, NJ
• LIST OF TABLES
• Summary Table:
• Table 1 DRUG DEVELOPMENT AND FDA APPROVAL PROCESS
• Table 2 NME APPROVALS GRANTED BY FDA (UNITED STATES), 1995-2004
• Table 3 TOTAL SPENDING ON R&D BY PHRMA COMPANIES, 1999-2003 ($ BILLIONS)
• Table 4 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
• Table 5 DRUG INEFFICACY, BY THERAPY TYPE (PERCENTAGE OF PATIENTS FAILING TO RESPOND TO THERAPY)
• Table 6 ADVERSE DRUG REACTIONS IN THE UNITED STATES
• Table 7 PROMINENT DRUGS WITHDRAWALS
• Table 8 SNP CONSORTIUM MEMBERS
• Table 9 HAPMAP PARTICIPANTS AND FUNDING SOURCES
• Table 10 STRUCTURE OF THE INTERNATIONAL HAPMAP PROJECT
• Table 11 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, THROUGH 2009 ($ MILLIONS)
• Table 12 EMERGING TECHNOLOGIES IN WHOLE GENOME MAPPING
• Table 13 MAJOR PRIVATE SNP DATABASES
• Table 14 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, THROUGH 2009 ($ MILLIONS)
• Table 15 COMPARATIVE ADVANATAGES OF ALLELIC DISCRIMINATION METHODS
• Table 16 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 17 TOTAL GLOBAL MICROARRAY MARKET AND THAT FOR GENOTYPING APPLICATIONS, THROUGH 2009 ($ MILLIONS)
• Table 18 COMPARATIVE ADVANATAGES OF DETECTION METHODS
• Table 19 STRENGTHS AND WEAKENESSES OF MASS SPECTROMETRY FOR GENOTYPING
• Table 20 EMERGING TECHNOLOGIES IN DNA MASS SPECTROMETRY
• Table 21 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 22 COMPARISON OF GENOTYPING PLATFORMS COST AND THROUGHPUT
• Table 23 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 24 MAJOR SUPPLIERS OF PLANAR DNA MICROARRAYS
• Table 25 MAJOR SUPPLIERS OF BEAD MICROARRAYS
• Table 26 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, THROUGH 2009 (MILLIONS $)
• Table 27 MAJOR SUPPLIERS OF PCR-BASED ASSAYS
• Table 28 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 29 COMPARISON OF FISH AND IHC TESTING FOR HER2
• Table 30 GLOBAL MARKET FOR IN SITU ASSAYS IN PHARMACOGENOMICS OF BREAST CANCER, THROUGH 2009 ($ MILLIONS)
• Table 31 PROJECTED BIDILR MARKET, THROUGH 2009 ($ MILLIONS)
• Table 32 MAJOR PRODUCERS OF STATINS
• Table 33 GLOBAL MARKET FOR HERCEPTIN, BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 34 GLOBAL MARKET FOR GLEEVEC/GLIVEC, BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 35 GLOBAL SALES OF IRESSA PRIOR TO FDA ANNOUNCEMENT, 2002-2004 ($ MILLIONS)
• Table 36 GENES OF INTEREST IN THE PHARMACOGENOMICS OF ASTHMA
• Table 37 MAJOR PLAYERS IN PHARMACOGENOMICS OF ASTHMA TREATMENT
• Table 38 GLOBAL MARKET FOR ASTHMA THERAPIES, BY TYPE, THROUGH 2009 ($ MILLIONS)
• Table 39 MAJOR SUPPLIERS OF HIV GENOTYPIC RESISTANCE TESTS
• Table 40 GLOBAL MARKET FOR HIV RESISTANCE TESTING BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 41 GLOBAL MARKET FOR ABACAVIR, BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 42 MAJOR CYTOCHROME P450 ISOZYMES
• Table 43 GLOBAL MARKET FOR AMPLICHIP ARRAYS IN DIAGNOSTIC USE BY REGION, THROUGH 2009 ($ MILLIONS)
• Table 44 MAJOR SUPPLIERS OF CYTOCHROME P450 TESTING FOR RESEARCH PURPOSES
• Table 45 PHARAMCOGENOMICS PATENTS BY TECHNOLOGY, 2004
• Table 46 PHARAMCOGENOMICS PATENTS BY DISEASE TARGET, 2004
• Table 47 PHARMACOGENOMICS PATENTS BY REGION, 2004
• Table 48 PHARMACOGENOMICS PATENTS BY ASSIGNEE, JANUARY 2004- JANUARY 2005
• Table 49 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 ($ MILLIONS)
• Table 50 KEY COLLABORATIONS IN THE PHARMACOGENOMICS INDUSTRY
• LIST OF FIGURES
• Summary Figure:
• Figure 1 R&D SPENDING ON CLINICAL DEVELOPMENT BY PHRMA COMPANIES, BY DRUG DEVELOPMENT PHASE, 2002 ($ BILLIONS)
• Figure 2 GLOBAL MARKET FOR SNP IDENTIFICATION TOOLS, 2001-2009 ($ MILLIONS)
• Figure 3 GLOBAL MARKET FOR GENOTYPING TECHNOLOGIES BY PROTOCOL, 2001-2009 ($ MILLIONS)
• Figure 4 GLOBAL MARKET FOR ALLELE DISCRIMINATION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 5 GLOBAL MARKET FOR GENOTYPING DETECTION TECHNOLOGIES BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 6 GLOBAL MARKET FOR PHARMACOGENOMICS DIAGNOSTIC TOOLS BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 7 GLOBAL MARKET FOR MICROARRAYS IN PHARMACOGENOMICS BY TYPE, 2001-2009 (MILLIONS $)
• Figure 8 GLOBAL MARKET FOR PCR ASSAYS IN PHARMACOGENOMICS RESEARCH BY TYPE, 2001-2009 ($ MILLIONS)
• Figure 9 GLOBAL MARKET FOR ABACAVIR, BY REGION, 2000-2009 ($ MILLIONS)
• Figure 10 MAJOR PHARMACOGENOMICS COMPANIES ANNUAL SALES AND MARKET SHARES, 2004 (%)